ClearPoint Neuro, Inc. is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.
The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision. Its proprietary SmartFrame trajectory guide offers adjustable angulation under MRI control, allowing clinicians to navigate complex cranial anatomy without the need for multiple frame placements or CT scans. The company also provides disposables, such as biopsy and ablation cannulae, to complement its core guidance platform.
Founded in 2007 as a spin-out from Brigham and Women’s Hospital, ClearPoint Neuro has secured regulatory clearances in the United States and Europe and has installed its systems in leading academic medical centers worldwide. The company’s commercial operations and clinical training programs support neurosurgeons and imaging specialists in North America, Europe and select international markets, fostering broader adoption of MRI-guided stereotactic procedures.
ClearPoint Neuro is led by a management team with deep expertise in medical devices, imaging and neurosurgery. The company continues to invest in product enhancements and clinical research partnerships, aiming to expand the range of neurological conditions that can benefit from its real-time, image-guided therapy solutions.
AI Generated. May Contain Errors.
